Literature DB >> 19497962

A potential link between peroxisome proliferator-activated receptor signalling and the pathogenesis of arrhythmogenic right ventricular cardiomyopathy.

Fatima Djouadi1, Yves Lecarpentier, Jean-Louis Hébert, Philippe Charron, Jean Bastin, Catherine Coirault.   

Abstract

AIMS: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is characterized by major fibro-fatty replacement of the right ventricle (RV). We hypothesized that changes in peroxisome proliferator-activated receptor (PPAR) signalling contributed to myocardium fatty accumulation and contractile dysfunction in ARVC. METHODS AND
RESULTS: Real-time quantitative reverse transcriptase-polymerase chain reaction and western blotting were used to assess cardiac expression of PPARalpha and gamma and two of their downstream target genes--medium-chain acyl-CoA dehydrogenase (MCAD) and phosphoenolpyruvate carboxykinase (PEPCK)--in both RV and left ventricle (LV) from five controls and five ARVC patients. In vitro motility assays were used to analyse functional properties of myosin. In the RV, sliding velocity was nearly two-fold lower in ARVC than in controls, whereas a 10% reduction in velocity values was noted between ARVC and non-failing myocardium in the LV. In controls, PPARalpha and MCAD mRNA and protein levels were higher in the RV compared with the LV. In ARVC, the expression of PPARalpha and MCAD mRNA and/or proteins was decreased in both RV and LV. RV from ARVC was also characterized by a dramatic activation of the PPARgamma pathway, as attested by the increase in PPARgamma mRNA and protein (500 and 270%, respectively, each P < 0.001) and by the induction of PEPCK gene. In contrast, the LV of ARVC heart exhibited no changes in the expression of the PPARgamma regulatory pathway compared with control.
CONCLUSION: ARVC is associated with major disturbances in the PPARalpha and PPARgamma signalling pathway in the RV that may contribute to intracellular lipid overload and severe myosin dysfunction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19497962     DOI: 10.1093/cvr/cvp183

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  29 in total

Review 1.  Evolving molecular diagnostics for familial cardiomyopathies: at the heart of it all.

Authors:  Thomas E Callis; Brian C Jensen; Karen E Weck; Monte S Willis
Journal:  Expert Rev Mol Diagn       Date:  2010-04       Impact factor: 5.225

2.  Plasma BIN1 correlates with heart failure and predicts arrhythmia in patients with arrhythmogenic right ventricular cardiomyopathy.

Authors:  Ting-Ting Hong; Rebecca Cogswell; Cynthia A James; Guson Kang; Clive R Pullinger; Mary J Malloy; John P Kane; Julianne Wojciak; Hugh Calkins; Melvin M Scheinman; Zian H Tseng; Peter Ganz; Teresa De Marco; Daniel P Judge; Robin M Shaw
Journal:  Heart Rhythm       Date:  2012-01-31       Impact factor: 6.343

Review 3.  Thermodynamics in Neurodegenerative Diseases: Interplay Between Canonical WNT/Beta-Catenin Pathway-PPAR Gamma, Energy Metabolism and Circadian Rhythms.

Authors:  Alexandre Vallée; Yves Lecarpentier; Rémy Guillevin; Jean-Noël Vallée
Journal:  Neuromolecular Med       Date:  2018-03-23       Impact factor: 3.843

4.  Blockade of the renin-angiotensin-aldosterone system in patients with arrhythmogenic right ventricular dysplasia: A double-blind, multicenter, prospective, randomized, genotype-driven study (BRAVE study).

Authors:  Elodie Morel; Ab Waheed Manati; Patrice Nony; Delphine Maucort-Boulch; Francis Bessière; Xu Cai; Timothee Besseyre des Horts; Alexandre Janin; Adrien Moreau; Phillippe Chevalier
Journal:  Clin Cardiol       Date:  2018-03-25       Impact factor: 2.882

5.  Arrhythmogenic right ventricular dysplasia back in force.

Authors:  Guy Fontaine; Huei-Sheng Vincent Chen
Journal:  Am J Cardiol       Date:  2014-03-14       Impact factor: 2.778

6.  Epicardial Fat Distribution Assessed with Cardiac CT in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy.

Authors:  Mounes Aliyari Ghasabeh; Anneline S J M Te Riele; Cynthia A James; H S Vincent Chen; Crystal Tichnell; Brittney Murray; John Eng; Brian G Kral; Harikrishna Tandri; Hugh Calkins; Ihab R Kamel; Stefan L Zimmerman
Journal:  Radiology       Date:  2018-08-21       Impact factor: 11.105

Review 7.  Opposite Interplay Between the Canonical WNT/β-Catenin Pathway and PPAR Gamma: A Potential Therapeutic Target in Gliomas.

Authors:  Alexandre Vallée; Yves Lecarpentier; Rémy Guillevin; Jean-Noël Vallée
Journal:  Neurosci Bull       Date:  2018-03-26       Impact factor: 5.203

Review 8.  Molecular mechanisms of arrhythmogenic cardiomyopathy.

Authors:  Karyn M Austin; Michael A Trembley; Stephanie F Chandler; Stephen P Sanders; Jeffrey E Saffitz; Dominic J Abrams; William T Pu
Journal:  Nat Rev Cardiol       Date:  2019-09       Impact factor: 32.419

9.  iASPP, a previously unidentified regulator of desmosomes, prevents arrhythmogenic right ventricular cardiomyopathy (ARVC)-induced sudden death.

Authors:  Mario Notari; Ying Hu; Gopinath Sutendra; Zinaida Dedeić; Min Lu; Laurent Dupays; Arash Yavari; Carolyn A Carr; Shan Zhong; Aaisha Opel; Andrew Tinker; Kieran Clarke; Hugh Watkins; David J P Ferguson; David P Kelsell; Sofia de Noronha; Mary N Sheppard; Mike Hollinshead; Timothy J Mohun; Xin Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-17       Impact factor: 11.205

Review 10.  Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug.

Authors:  Lorenzo Nesti; Domenico Tricò; Alessandro Mengozzi; Andrea Natali
Journal:  Cardiovasc Diabetol       Date:  2021-05-18       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.